APPROVED – CSU IBC Meeting Minutes

Meeting title	CSU IBC Meeting July 2025
Date	July 9, 2025
Convened at	12:01PM MST
Location	Microsoft Teams (Virtual Meeting)
Open or closed meeting (If closed, why?)	Open Meeting
Review of prior meeting minutes	May 14, 2025 meeting minutes were approved as written; No meeting was held in June 2025
Adjournment	1:16PM MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	**Check if Attending (Alternate Members):**
☒ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☒ Donald Bade, Unaffiliated	
☒ Angela Bosco-Lauth, Veterinary Virology	
☒ Chaoping Chen, Chair	
☒ Jason Cummings, lab representative	
☐ Dan Frazen, Unaffiliated	
☒ Rebekah Kading, Virology	
☒ Jean Peccoud, Synthetic Biology	
☒ Brendan Podell, Mycobacteria specialist	
☒ Ann Powers, Virology	
☒ Robyn Roberts, Plant expert	
☐ Joanie Ryan, Assistant Biosafety Director	☐ Rebecca Moritz, Biosafety Office Director
☐ Tony Schountz, Virology (on sabbatical)	☒ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; 10 in attendance	*non-voting at this meeting
Non-Voting Members:	
☒ James Graham, EHS Director	
☐ Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
☒ Michelle Ramey, Assistant Compliance Coord.	☒ Sonia Aleman Rivera, Assistant Biosafety Officer
☐ Nicole Marlenee, Biosecurity Specialist	☒ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Linda Schutjer, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Agent/Project Review

a. PI name/Lab	Moreira Lab
Project Number and Title	**25-044B: Food Safety Research- Moreira Lab**
Agents used	• *Escherichia coli* O157- and non-O157 Shiga toxin producing • *Listeria monocytogenes* • *Salmonella spp.*
Project Overview	This project will evaluate survival of the above agents on different types of food-contact surfaces (i.e. stainless steel) and vegetative tissues (i.e. microgreens from the Brassicaceae family (red cabbage, broccoli, and radish)).
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL-2
Discussion	This is a new PI/Lab in the Department FSHN 1. For the question "Are there any health restrictions for handling these agents?" the answer should be changed to YES, as pregnant women must be especially careful. 2. For all 3 Pathogen Registration Forms, in Step III, the committee requests the PI specify the disinfectant(s) used for decontamination of surfaces. It was recommended to adjust the spill clean-up procedure slightly - Cover the entire spill with absorbent material like paper towels, pour disinfectants over the paper towels from the outside in (circular motion), completely saturating them, and allow it to sit for the contact time. Then proceed with the clean-up from the outside in. 3. The location of the stomacher during homogenization should be specified, including whether it is in a biosafety cabinet. Where will the whirl-pak's be opened? 4. A statement indicating how waste is disposed of should be added, including what disinfectants are used, the concentration, and contact time.
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	A Biosafety Outreach Visit needs to be scheduled.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

b. PI name/Lab	Gonzalez-Juarrero Lab
Project Number and Title	**16-047B: Inhalational therapy with spectinamides within new regimens of TB therapy**
Agents used	• *Mycobacterium avium complex* (MAC) • *Mycobacterium tuberculosis*
Project Overview	Testing various inhalational therapy regiments for their effectiveness against MTB in mouse models.

Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Project Number and Title	**23-007B: NTM Center: In vitro and in vivo testing of therapies for non-tuberculous mycobacterial infections**
Agents used	• *Mycobacterium abscessus* • *Mycobacterium avium complex* (MAC) • *Mycobacterium kanssasi*
Project Overview	The project involves testing a variety of therapeutic compounds against NTMs, using in vitro methods like MICs or using in vivo mouse models.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Project Number and Title	**19-092B: Tailoring modifications of polysaccharides in Mycobacterium tuberculosis**
Agents used	• *Mycobacterium tuberculosis* • *Mycobacterium bovis BCG*
Project Overview	Several MTB strains with modifications in the cell wall will be made by a different lab (under a separate IBC approval). In this project, these strains will be tested in mice to see if there is a difference in immunological responses elicited by the mice.
Planned Modifications	Infecting mice with modified organism
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Discussion	This is an established PI in MIP. All 3 projects have previously been reviewed and approved; several updates were recently made requiring re-review. For #16-047B: 1. It is unclear how Mtb H37Ra, MAC, and M.bovis BCG are used for in this project; request clarification. 2. Project mentions that tyveks will be used occasionally. Please describe in what instance a tyvek would be used. 3. The IBC requests clarification whether M. avium is worked with at A/BSL2 or A/BSL3. If used at A/BSL-2, PPE and animal carcass handling differences need to be specified. For #19-092B: 4. The committee requests a brief description of how M. bovis BCG is used be added in the overview. 5. If personnel can choose PAPR or N95 for in vitro work, update description to "safety glasses and an N95 or PAPR every

	time..." Also, remove statement about disposable PPE since not all of those items are disposable. For #23-007B: 6. It appears that multiple PIs are responsible for the biosafety aspects of the work. If so, they all need to be included in the personnel list, under "Other individuals involved in this project". 7. There are some discrepancies regarding whether the work occurs at A/BSL-2 or A/BSL-3. The work can be done at A/BSL2. Request clarification/update of the locations. 8. Vespin should be vesphene throughout - is correct in other areas. 9. Are animal carcasses double or triple bagged for autoclaving? This project says triple, the other two say double. For all 3 projects: 10. The specific disinfectant used should be listed, along with its concentration, and the contact time. 11. The phrase "Every day new PPE is used" should be reworded to indicate that new PPE is used every time someone goes into the lab. 12. Responses to Microbial Agent survey questions should be modified to explain work with all pathogenic agents in the lab.
Verification of training	A few lab members need to update training; the PI will be informed.
Verification of facilities	The lab recently had its annual inspection.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

c. PI name/Lab	**Vilander Lab**
Project Number and Title	**25-042B: Recombinant Lactobacillus for oral vaccination of avian reservoirs against West Nile virus**
Agents used	• *Lactobacillus acidophilus* • *West Nile virus* (WNV)
Project Overview	This project aims to develop an oral WNV vaccine platform that can be added to wild bird feed
Planned Modifications	Lactobacillus acidophilus will be modified to express WNV surface glycoproteins (rLA-WNV)
NIH Guidelines Section	III-D-2/III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL-2/ABSL-2 in birds
Discussion	This is an experienced PI in MIP. 1. The Description of Experimental and Procedural Details contains a lot of information related to the animal procedures that are not relevant to the IBC review. The information

	should be trimmed down to the pertinent details regarding use of WNV and WNV infected materials. 2. It is unclear where/how the rLA-WNV will be obtained. For example, was it made by a colleague? Will it be cultured in your lab? More information requested. 3. There is a discrepancy in the ABSL2 work locations. This needs to be clarified/updated. 4. The IBC requests more information regarding what assays will be used on blood samples collected from immunized and WNV-challenged birds. For the WNV Pathogen Form: 5. The strain should be added (it's listed elsewhere) 6. More information about sharps used to in blood collection from WNV-infected birds should be added. 7. Since WNV will be used at A/BSL2 instead of A/BSL3, the Biocontainment Animal Housing question should be changed to Yes and the risk group and biosafety level should be changed to 2.
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

d. PI name/Lab	**Vivanco Lab**
Project Number and Title	**25-045B: Rhizosphere Biology**
Agents used	• *Achromobacter xylosoxidans*
Project Overview	This project investigates the phosphorus (P) responsiveness of *Achromobacter xylosoxidans*, a soil-dwelling bacterium
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	This is an experienced PI in HLA 1. Request clarification of the culturing conditions. Will the bacteria strictly be grown on agar media? Will any liquid media be used? 2. The incubator be location should be specified. 3. How will the microbe be stored in the short and long term? 4. Since not all the isolates are from Colorado, the PI should confirm with APHIS and add a comment in the Authorizations and Permits section regarding whether or not a permit is needed. For the Agent Form

	5. The IBC requests "10% bleach" be defined in terms of actual sodium hypochlorite concentration. 2) 6. The IBC recommends that a Class II biosafety cabinet be used and the answer to the BSC question changed from NO to YES.
Verification of training	All lab members have completed the required training in SciShield.
Verification of facilities	The lab is previously approved for BSL1; they need to schedule a Biosafety Outreach visit to upgrade to BSL2.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

2. Amendments requiring full IBC review

a. PI name/Lab	**Gentry-Weeks Lab**
Project Number and Title	**22-071B: Development of a minimal phage for delivery of bacteriolytic agents**
Agents used	• *Escherichia coli* • *Lactobacillus salivarius* • *Pediococcus acidilactici* • *Staphylococcus aureus* (MRSA) • *Staphylococcus simulans* • *Staphylococcus aureus*
Project Overview	The goal of this project is to identify essential phage genes and to deliver bacteriolytic agents via the phage to kill bacteria.
Amendment request	use CRISPR-Cas9 and sguide RNA to knock out P68 genes
Planned Modifications	deliver CRISPR-Cas9 and sguide RNA to phage P68 to knock out P68 genes
NIH Guidelines Section	III-D-2
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	CRISPR is being added as another delivery method to knock out genes in phage. No concerns noted by the IBC.
Verification of training	All lab members are up to date on required training.
Verification of facilities	The is up to date on lab inspections.
Motion	A motion was made to approve the amendment request as written.
Vote	The motion was unanimously approved.

3. New Business – none

4. Unfinished Business

a. Business item	**McGrath Lab** **Project:** Evaluation of Genetically Engineered L-DOPA Bacterial Live-Therapeutics (LDBL) in a Canine Model of Cognitive Dysfunction (25-00B); BSL1/ABSL1 in client owned dogs, rDNA. NIH Guidelines category non-exempt rDNA: III-D-4
Discussion	Project previously reviewed during May 2025 Meeting; it was approved with modifications and pending receipt of additional documentation. The modifications have been made and documents uploaded. The committee reviewed the updates and the additional documents and had a couple additional questions: • Clarify whether the agent will be manipulated at CSU or not. • Clarify the PPE that will be used for different tasks.
Motion	A motion was made to approve the Lab registration pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.
b. Business item	**New IBC minutes requirements from NIH/update to minutes format**
Discussion	The IBC Manager reminded the IBC that going forward, meeting minutes will be posted on CSU's IBC website. The committee reviewed the updated minutes template, along with the updated Meeting and Minutes SOP. The IBC will utilize the option to close the meeting to discuss sensitive topics that do not involve work subject to the NIH Guidelines. This is described in the SOP and includes personal, proprietary, and/or security issues. Since there was no meeting in June, the first minutes to be posted will be from the July meeting. They will be posted in August, after they have been approved by the committee and reviewed by OGC.
Action Item	This was an FYI, no vote or action item required.

5. Reports

a. Coordinator's Report	Next IBC meeting: Wednesday, August 13, 2025
b. Biosafety Office Report	None

6. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After	**Pezzanite Lab** **1. Pathogen Registration Forms** a. Bacteria - *Staphylococcus aureus* ATCC 25923

Modification were completed	b. Bacteria - *Escherichia coli* c. Bacteria - Bacteria Xen36 *Staphylococcus aureus* ATCC 49525 2. **Project:** OTA - Biologically compatible volume-filling medical foam for local antibiotic delivery in fractures (25-022B); BSL2/ABSL2 in rats, rDNA. NIH Guidelines category non-exempt rDNA: III-D-4 3. **Project:** DOD CDMRP PRMRP - Multifunctional medical foam to enhance acute wound management in mouse model (25-023B); BSL2/ABSL2 in mice, rDNA. NIH Guidelines category non-exempt rDNA: III-D-4 4. **Project:** Incrediwear - Evaluation of germanium fabrics to improve wound healing and eradicate infection (25-024B); BSL2. NIH Guidelines category non-exempt rDNA: III-D-4
b. Items Reviewed and Approved by the Biosafety Officer or Chair since the last meeting	None